Menu
Menu
In the production of therapeutic biologics and advanced pharmaceuticals, ensuring the highest level of purity is essential. One of the most significant challenges in biologic manufacturing is managing elemental impurities, such as trace metals and other non-essential elements. These impurities can cause adverse effects during upstream cell culture processes and in the final formulation of parenteral injectable drugs. Strict regulatory guidelines, such as ICH Q3D, govern the acceptable levels of elemental impurities, making their control crucial for product safety and efficacy.
Pfanstiehl addresses this challenge by utilizing proprietary processes that significantly reduce elemental impurities, often to single-digit parts per billion (ppb) levels – 100 to 1000 times less than the current industry standards. This exceptional level of purity helps mitigate the risks associated with elemental impurities, ensuring high-quality therapeutic biologics that meet stringent regulatory requirements.
In therapeutic biologics, cell culture systems are used to produce complex proteins. The presence of even trace amounts of elemental impurities can disrupt the delicate balance required for optimal protein production. Pfanstiehl’s proprietary processes ensure that cell culture ingredients contain drastically reduced levels of these impurities, which leads to several critical benefits.
Enzymatic reactions are essential in biologic production, facilitating protein synthesis and necessary post-translational modifications. Elemental impurities, such as copper and zinc, can inhibit enzymes by binding to their active sites or altering their structures. By lowering these impurities to levels far below industry standards, Pfanstiehl helps maintain enzymatic function, leading to improved protein synthesis and post-translational fidelity, such as glycosylation, which is crucial for the efficacy of therapeutic proteins.
Proper glycosylation is vital for the stability, efficacy, and biological activity of therapeutic proteins. Trace metals, such as zinc and copper, can interfere with the enzymes responsible for adding carbohydrate groups to proteins, causing disruptions in the glycosylation process. These disruptions can result in altered glycosylation patterns, leading to proteins that are improperly folded, less stable, and potentially more immunogenic. This can severely impact the therapeutic efficacy of biologics. By using cell culture ingredients with ultra-low levels of elemental impurities, Pfanstiehl ensures that glycosylation patterns remain consistent and correct, contributing to the production of high-quality, effective biologics.
Elemental impurities can also contribute to protein misfolding and aggregation, which compromises the overall quality of the biologic. Protein aggregation is particularly concerning because it can lead to lower yields of functional proteins and increase the risk of immunogenicity. Pfanstiehl’s ingredients, with exceptionally low levels of impurities, minimize the risk of aggregation, ensuring higher yields of biologically active, properly folded proteins.
In parenteral biologics, the final formulation is directly administered to patients, making the purity of excipients critical to the safety and efficacy of the drug. Even minimal elemental impurities can degrade therapeutic proteins, increase the risk of adverse immune reactions, or reduce drug stability. Pfanstiehl’s proprietary processes ensure that cGMP parenteral excipients contain elemental impurities at levels far below industry norms, which has a significant impact on drug safety and performance.
Elemental impurities, particularly metals such as iron, can catalyze oxidation reactions that degrade proteins. This degradation reduces the drug’s stability, efficacy, and shelf life. Pfanstiehl’s excipients, which achieve single-digit ppb impurity levels, minimize the potential for these catalytic reactions, ensuring a more stable and longer-lasting therapeutic product.
When proteins degrade or aggregate due to elemental impurities, they can trigger immune responses in patients. Immunogenicity is a major concern in biologic drugs, as it can reduce efficacy and provoke adverse immune reactions, including the development of anti-drug antibodies (ADAs). By reducing impurities to levels 100 to 1000 times lower than current industry standards, Pfanstiehl’s excipients significantly lower the risk of immunogenicity, contributing to a safer, more effective therapeutic product.
Elemental impurities such as lead, mercury, and arsenic are highly toxic when introduced into the bloodstream, even in trace amounts. Pfanstiehl’s proprietary processes ensure that their excipients contain minimal toxic elements, greatly enhancing patient safety by preventing systemic toxicity, organ damage, and other adverse effects associated with these contaminants.
Pfanstiehl’s industry-leading, proprietary processes allow us to produce cell culture ingredients and cGMP parenteral excipients with exceptionally low levels of elemental impurities. By reducing impurities to single-digit ppb level -100 to 1000 times lower than traditional industry standards – Pfanstiehl’s products provide a new benchmark for purity in therapeutic biologic production. These ultralow levels of impurities bring a host of critical advantages:
Pfanstiehl knows that elemental impurities are a serious concern in both upstream cell culture processes and final formulations of parenteral biologics. Even trace levels of metals and other elements can significantly impact protein yields, drug stability, patient safety, and regulatory compliance. Pfanstiehl’s proprietary processes, which reduce elemental impurities to single-digit ppb levels, provide a critical solution to these challenges.
By offering cell culture ingredients, APIs, and cGMP parenteral excipients with impurity levels 100 to 1000 times lower than current industry standards, Pfanstiehl helps manufacturers produce safer, more effective biologics, while also ensuring compliance with the most stringent regulatory standards.